62484-39-3

Usage

Uses

Used in Pharmaceutical Industry:
4(1H)-Quinazolinone, 2,8-dichlorois used as a key intermediate compound for the synthesis of potent CXCR2 antagonists and dipeptidyl peptidase IV (DPP-IV) inhibitors. These inhibitors play a crucial role in the development of drugs targeting various diseases, including type 2 diabetes, inflammatory disorders, and certain types of cancer.
CXCR2 antagonists, derived from 4(1H)-Quinazolinone, 2,8-dichloro-, are employed for their anti-inflammatory properties, making them potential candidates in the treatment of chronic obstructive pulmonary disease (COPD), asthma, and other inflammatory conditions.
DPP-IV inhibitors, on the other hand, are used to manage type 2 diabetes by regulating glucose levels in the body. They work by slowing down the degradation of incretin hormones, which stimulate insulin secretion and reduce glucose production in the liver.

Upstream product

• 6388-47-2 2-amino-3-chlorobenzoic acid 
• 62484-29-1 2,4,8-trichloroquinazoline 
• 62484-22-4 8-chloro-2,4-dioxo-1,2,3,4-tetrahydroquinazoline 

Downstream Products

• 769158-11-4 2-((2,8-dichloro-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile 
• 19407-55-7 8-Chloro-2-phenylquinazolin-4(3H)-one 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS

The invention relates to heterocyclic compounds and their use as antibiotics and/or as antibiotic potentiators. The compounds may act as colistin potentiators and SOS inhibitors.

Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4). Herein, we describe the structure-based design and optimization of alogliptin and related quinazolinone-based DPP-4 inhibitors. Following an oral dose, these noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and a lowering of blood glucose in animal models of diabetes. Alogliptin is currently undergoing phase 111 trials in patients with type 2 diabetes.

Tetrazolo[A]quinazol-5-ones antiallergy and antiulcer agents

A series of tetrazolo[a]quinazol-5-ones, methods for their production and use as antiallergy agents and antiulcer agents.